



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 37/02 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/075680

(22) International Filing Date:

30 August 2022 (30.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/238,443 30 August 2021 (30.08.2021) US
63/334,923 26 April 2022 (26.04.2022) US

(71) Applicant: LASSEN THERAPEUTICS 1, INC.
[US/US]; 9215 Brown Deer Road, Suite C, San Diego, California 92121 (US).

(72) Inventors: HORLICK, Robert A.; c/o Lassen Therapeutics 1, Inc., 9215 Brown Deer Road, Suite C, San Diego, California 92121 (US). JUN, Helen Toni; c/o Lassen Therapeutics 1, Inc., 9215 Brown Deer Road, Suite C, San


Diego, California 92121 (US). KING, David J.; c/o Lassen Therapeutics 1, Inc., 9215 Brown Deer Road, Suite C, San Diego, California 92121 (US).

(74) Agent: CHRISTIANSEN II, William T. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: ANTI-IL-11RA ANTIBODIES



(57) Abstract: Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11R α) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*